PMID- 25470298
OWN - NLM
STAT- MEDLINE
DCOM- 20150714
LR  - 20200225
IS  - 1932-8737 (Electronic)
IS  - 0160-9289 (Print)
IS  - 0160-9289 (Linking)
VI  - 37
IP  - 12
DP  - 2014 Dec
TI  - Efficacy and safety of dronedarone in patients previously treated with other 
      antiarrhythmic agents.
PG  - 717-24
LID - 10.1002/clc.22342 [doi]
AB  - BACKGROUND: Currently available antiarrhythmic drugs (AADs) for the prevention of 
      atrial fibrillation (AF)/atrial flutter (AFL) suffer from incomplete efficacy and 
      poor tolerability. HYPOTHESIS: Dronedarone could represent an effective and safe 
      option in patients previously treated with AADs, especially class Ic AADs and 
      sotalol. METHODS: Retrospective analysis of 2 double-blind, parallel-group trials 
      (EURIDIS [European Trial in Atrial Fibrillation or Flutter Patients Receiving 
      Dronedarone for the Maintenance of Sinus Rhythm] and ADONIS 
      [American-Australian-African Trial With Dronedarone in Atrial Fibrillation or 
      Flutter Patients for the Maintenance of Sinus Rhythm]) comparing the efficacy and 
      safety of dronedarone with placebo over 12 months. The primary end point was 
      AF/AFL recurrence in patients previously treated with another AAD that was 
      discontinued for whatever reason prior to randomization. RESULTS: In patients 
      previously treated with any AADs, dronedarone decreased the risk of AF recurrence 
      by 30.4% vs placebo (hazard ratio [HR]: 0.70; 95% confidence interval [CI]: 
      0.59-0.82; P < 0.001). In patients previously treated with a class Ic agent, 
      dronedarone decreased the risk of recurrence by 31.4% (HR: 0.69; 95% CI: 
      0.53-0.89; P = 0.004), whereas in patients previously treated with sotalol, 
      dronedarone showed a trend toward a decrease of risk of recurrence (HR: 0.86; 95% 
      CI: 0.67-1.11; P = 0.244). Dronedarone was equally effective irrespective of 
      whether class Ic or sotalol were stopped for lack of efficacy or adverse events 
      (AEs). Discontinuation rates were similar in the 2 groups (55.9% vs 43.1%), as 
      were incidence of AEs and serious AEs. CONCLUSIONS: Dronedarone seems to be 
      effective in preventing AF recurrences in patients without permanent AF 
      previously treated with other AADs, even if those were discontinued for lack of 
      efficacy. Dronedarone appears to be well tolerated even in patients who already 
      had tolerability issues with AADs.
CI  - (c) 2014 Wiley Periodicals, Inc.
FAU - Guerra, Federico
AU  - Guerra F
AD  - Department of Cardiology, Marche Polytechnic University, Ancona, Italy.
FAU - Hohnloser, Stefan H
AU  - Hohnloser SH
FAU - Kowey, Peter R
AU  - Kowey PR
FAU - Crijns, Harry J G M
AU  - Crijns HJ
FAU - Aliot, Etienne M
AU  - Aliot EM
FAU - Radzik, David
AU  - Radzik D
FAU - Roy, Denis
AU  - Roy D
FAU - Connolly, Stuart
AU  - Connolly S
FAU - Capucci, Alessandro
AU  - Capucci A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20141202
PL  - United States
TA  - Clin Cardiol
JT  - Clinical cardiology
JID - 7903272
RN  - 0 (Anti-Arrhythmia Agents)
RN  - A6D97U294I (Sotalol)
RN  - JQZ1L091Y2 (Dronedarone)
RN  - N3RQ532IUT (Amiodarone)
SB  - IM
MH  - Amiodarone/administration & dosage/*analogs & derivatives/therapeutic use
MH  - Anti-Arrhythmia Agents/*administration & dosage/*therapeutic use
MH  - Atrial Fibrillation/*drug therapy
MH  - Atrial Flutter/*drug therapy
MH  - Double-Blind Method
MH  - Dronedarone
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Recurrence
MH  - Retrospective Studies
MH  - Sotalol/administration & dosage/therapeutic use
PMC - PMC6647669
EDAT- 2014/12/04 06:00
MHDA- 2015/07/15 06:00
PMCR- 2014/12/02
CRDT- 2014/12/04 06:00
PHST- 2014/08/01 00:00 [received]
PHST- 2014/09/04 00:00 [revised]
PHST- 2014/09/05 00:00 [accepted]
PHST- 2014/12/04 06:00 [entrez]
PHST- 2014/12/04 06:00 [pubmed]
PHST- 2015/07/15 06:00 [medline]
PHST- 2014/12/02 00:00 [pmc-release]
AID - CLC22342 [pii]
AID - 10.1002/clc.22342 [doi]
PST - ppublish
SO  - Clin Cardiol. 2014 Dec;37(12):717-24. doi: 10.1002/clc.22342. Epub 2014 Dec 2.